CDx Diagnostics to Present Clinical Data on Device for Esophageal Cancer Detection

Suffern, N.Y.-based CDx Diagnostics completed a clinical study on its Wide Area Transepithelial Sample for detecting cancer of the biliary tract.
The company's studies have evidence that supports using the WATS device to monitor patients who have received ablation therapy for esophageal pre-cancer.

A WATS biopsy collects a wide area of tissue that is then given a computer-assisted 3-D analysis to pinpoint problematic cells.

Representatives from the company will present their clinical data at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course this weekend.

More Articles on Gastroenterology:
Gastric Cancer Foundation, American Gastroenterological Association Team Up to Provide $2.25M in Research Grants
Today Olympus Launches New Ultrasound Gastrovideoscope
Jay Monahan Center for Gastrointestinal Health Names Dr. Fleice Schnoll-Sussman Director

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast